Trial Type
Follow-Up Treatment (Metastatic Disease)
Description for experts
A Phase 1 Single-Arm, Open-Label Study of CA-4948 in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease.
Description for laymen
A single-arm, open-label, phase 1 study of CA-4948 in combination with azacitidine Combination with azacitidine and venetoclax in patients with acute myeloid leukemia after complete response with measurable residual deficiency Residual disease.
JSON Data
{
"short_title": "CURIS CA-4948-104",
"data_mode": "900",
"data_mode_number": "000002312",
"official_title": "A PHASE 1 SINGLE-ARM, OPEN-LABEL STUDY OF CA-4948 IN COMBINATION WITH AZACITIDINE AND VENETOCLAX \r\nIN ACUTE MYELOID LEUKEMIA PATIENTS IN COMPLETE RESPONSE WITH MEASURABLE RESIDUAL DISEASE.",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "gtThird",
"ctgov_number": null,
"eudract_number": "2023-505828-58",
"general_contact_email": "ectu@ukdd.de",
"general_contact_phone": "+49 351-4587566",
"hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke",
"description_laie_de": "Eine einarmige, offene Phase-1-Studie mit CA-4948 in Kombination mit Azacitidin Kombination mit Azacitidin und Venetoclax bei Patienten mit akuter myeloischer Leuk\u00e4mie nach vollst\u00e4ndigem Ansprechen mit messbarem Restmangel Resterkrankung.",
"description_laie_en": "A single-arm, open-label, phase 1 study of CA-4948 in combination with azacitidine Combination with azacitidine and venetoclax in patients with acute myeloid leukemia after complete response with measurable residual deficiency Residual disease.",
"description_expert_de": "Eine einarmige, offene Phase-1-Studie mit CA-4948 in Kombination mit Azacitidin Kombination mit Azacitidin und Venetoclax bei Patienten mit akuter myeloischer Leuk\u00e4mie nach vollst\u00e4ndigem Ansprechen mit messbarem Restmangel Resterkrankung.",
"description_expert_en": "A Phase 1 Single-Arm, Open-Label Study of CA-4948 in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "I",
"main_cat_id": 4,
"sub_cat_id": 30
}
